Lab
Providence Health & Services Washington
Providence Health & Services Washington was paid $9.29M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 18% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES WASHINGTON
SPOKANE, WA 99204
SPOKANE, WA 99204
33aNPI1902141500assigned 12/07/2012
33bProvider typeClinical Medical Laboratory
28Total paid$9.29M
24GClaims489,385
24DCodes billed104
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Washington
Rank by total paid#10 of 76
Median peer was paid$90K
This provider vs. median103×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,435 | $660K | |
| 2019 | 54,881 | $891K | |
| 2020 | 48,280 | $730K | |
| 2021 | 76,606 | $1.38M | |
| 2022 | 89,012 | $2.20M | |
| 2023 | 88,329 | $1.73M | |
| 2024incomplete | 87,842 | $1.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 18% | 12,609 | 12,430 | $1.71M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 10% | 27,899 | 27,383 | $966K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.8% | 12,326 | 11,749 | $911K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.1% | 8,448 | 8,356 | $753K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.7% | 10,710 | 10,479 | $529K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.1% | 11,456 | 11,158 | $381K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.1% | 11,456 | 11,156 | $379K |
| 36415 | Collection of venous blood by venipuncture | 3.4% | 79,154 | 73,476 | $317K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.2% | 9,079 | 8,896 | $299K |
| 80050 | General health panel | 3.1% | 9,708 | 9,652 | $289K |
| 80053 | Comprehensive metabolic panel | 2.9% | 29,870 | 28,807 | $272K |
| 80061 | Lipid panel | 2.3% | 21,006 | 20,752 | $218K |
92 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 2.2% | 15,086 | $206K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 27,318 | $192K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.6% | 6,947 | $152K |
| 87631 | 1.3% | 957 | $125K | |
| 87634 | 1.3% | 1,788 | $119K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,850 | $92K |
| 84703 | <1% | 11,338 | $84K | |
| 86803 | <1% | 6,506 | $81K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,279 | $80K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,201 | $68K |
| 82607 | <1% | 4,904 | $66K | |
| 81001 | <1% | 20,523 | $62K | |
| 87505 | <1% | 470 | $54K | |
| 85027 | <1% | 9,478 | $52K | |
| 86480 | <1% | 793 | $44K | |
| 80306 | <1% | 2,730 | $42K | |
| 86780 | <1% | 3,381 | $42K | |
| 84466 | <1% | 3,656 | $41K | |
| 82746 | <1% | 2,697 | $35K | |
| 84439 | <1% | 4,374 | $35K | |
| 86140 | <1% | 6,386 | $31K | |
| 83021 | <1% | 1,690 | $26K | |
| 83540 | <1% | 4,486 | $26K | |
| 82728 | <1% | 2,015 | $25K | |
| 84153 | <1% | 1,620 | $25K | |
| 87210 | <1% | 4,598 | $24K | |
| 83735 | <1% | 4,048 | $24K | |
| 83970 | <1% | 684 | $24K | |
| 81003 | <1% | 11,082 | $24K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 178 | $24K |
| 84403 | <1% | 1,049 | $23K | |
| 82570 | <1% | 4,796 | $22K | |
| 82043 | <1% | 4,114 | $21K | |
| 83690 | <1% | 2,624 | $17K | |
| 83880 | <1% | 510 | $17K | |
| 99001 | <1% | 685 | $16K | |
| 85652 | <1% | 6,026 | $15K | |
| 87340 | <1% | 1,567 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 937 | $14K |
| 83001 | <1% | 748 | $13K | |
| 85379 | <1% | 1,074 | $10K | |
| 86706 | <1% | 1,023 | $10K | |
| 86308 | <1% | 2,009 | $10K | |
| 80069 | <1% | 1,258 | $10K | |
| 82784 | <1% | 675 | $9K | |
| 84146 | <1% | 439 | $8K | |
| 84702 | <1% | 559 | $8K | |
| 86038 | <1% | 645 | $7K | |
| 82247 | <1% | 1,495 | $7K | |
| 87506 | <1% | 25 | $6K | |
| 84100 | <1% | 1,481 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 199 | $6K |
| 83550 | <1% | 674 | $6K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 146 | $6K |
| 80076 | <1% | 756 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 211 | $5K |
| 83013 | <1% | 69 | $4K | |
| 84550 | <1% | 1,014 | $4K | |
| 82248 | <1% | 863 | $4K | |
| 84156 | <1% | 1,194 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,151 | $4K |
| 83002 | <1% | 163 | $3K | |
| 86431 | <1% | 511 | $3K | |
| 86592 | <1% | 671 | $3K | |
| 81015 | <1% | 865 | $3K | |
| 87481 | <1% | 54 | $3K | |
| 36416 | <1% | 1,037 | $2K | |
| 84484 | <1% | 214 | $2K | |
| 80305 | <1% | 185 | $2K | |
| 84480 | <1% | 158 | $2K | |
| 86762 | <1% | 142 | $2K | |
| 82565 | <1% | 329 | $2K | |
| 87529 | <1% | 26 | $2K | |
| 84460 | <1% | 302 | $1K | |
| 82533 | <1% | 70 | $1K | |
| 82274 | <1% | 56 | $888.98 | |
| 84450 | <1% | 150 | $700.52 | |
| 82550 | <1% | 68 | $430.93 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 27 | $407.28 |
| 85018 | <1% | 139 | $322.66 | |
| 85049 | <1% | 71 | $300.61 | |
| 81025 | <1% | 30 | $264.83 | |
| 85014 | <1% | 110 | $254.01 | |
| 82150 | <1% | 39 | $249.18 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 15 | $247.55 |
| 82977 | <1% | 33 | $220.75 | |
| 86704 | <1% | 38 | $186.79 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18 | $92.83 |
| 82950 | <1% | 20 | $90.90 | |
| 85046 | <1% | 15 | $74.68 | |
| 84132 | <1% | 13 | $70.19 | |
| 82947 | <1% | 16 | $44.20 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.